Engineered immune cells take on tough lupus cases
NCT ID NCT05798117
First seen Nov 11, 2025 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. YTB323 uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The trial will enroll 21 adults and focus on safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Pessac, 33604, France
-
Novartis Investigative Site
Strasbourg, 67091, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Bern, 3010, Switzerland
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.